STOCK TITAN

[Form 4] Merus N.V. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Colony Bankcorp Inc. (CBAN) Form 4 highlights: Director Matthew D. Reed reported the grant of 969 restricted shares on 07/15/2025. Following the award, he now directly owns 16,736 common shares, up roughly 6% from the pre-grant level (~15,767). In addition, Reed holds 448 shares indirectly through an IRA for Kennedy K. Reed. No derivative securities, sales, or open-market purchases were disclosed.

The filing reflects a routine equity-based compensation grant and modestly increases insider ownership, which can align director incentives with shareholder interests. However, because the shares were granted (not purchased with personal funds), the transaction’s immediate signaling value is limited. No other material events, financial metrics, or changes to ownership structure were reported.

Colony Bankcorp Inc. (CBAN) - Evidenze del Modulo 4: Il direttore Matthew D. Reed ha segnalato la concessione di 969 azioni vincolate il 15/07/2025. Dopo questa assegnazione, detiene ora direttamente 16.736 azioni ordinarie, con un aumento di circa il 6% rispetto al livello precedente (~15.767). Inoltre, Reed possiede 448 azioni indirettamente tramite un IRA intestato a Kennedy K. Reed. Non sono state dichiarate operazioni su titoli derivati, vendite o acquisti sul mercato aperto.

La comunicazione riguarda una concessione ordinaria di azioni come parte della remunerazione basata su equity e incrementa moderatamente la partecipazione interna, potenzialmente allineando gli interessi del direttore con quelli degli azionisti. Tuttavia, poiché le azioni sono state assegnate (e non acquistate con fondi personali), il valore informativo immediato dell’operazione è limitato. Non sono stati riportati altri eventi rilevanti, indicatori finanziari o variazioni nella struttura proprietaria.

Colony Bankcorp Inc. (CBAN) - Destacados del Formulario 4: El director Matthew D. Reed informó la concesión de 969 acciones restringidas el 15/07/2025. Tras esta adjudicación, posee directamente 16,736 acciones comunes, un aumento aproximado del 6% respecto al nivel previo (~15,767). Además, Reed tiene 448 acciones indirectamente a través de una cuenta IRA para Kennedy K. Reed. No se divulgaron operaciones con valores derivados, ventas ni compras en mercado abierto.

La presentación refleja una concesión rutinaria de compensación basada en acciones y aumenta modestamente la propiedad interna, lo que puede alinear los incentivos del director con los intereses de los accionistas. Sin embargo, dado que las acciones fueron otorgadas (y no compradas con fondos personales), el valor informativo inmediato de la transacción es limitado. No se reportaron otros eventos materiales, métricas financieras ni cambios en la estructura de propiedad.

Colony Bankcorp Inc. (CBAN) Form 4 주요 내용: 이사 Matthew D. Reed가 2025년 7월 15일에 969주의 제한 주식 부여를 보고했습니다. 이번 부여 이후 그는 현재 직접 16,736주의 보통주를 보유하고 있으며, 부여 전 약 6%(약 15,767주) 증가한 수치입니다. 또한 Reed는 Kennedy K. Reed 명의의 IRA를 통해 간접적으로 448주를 보유하고 있습니다. 파생 증권, 매도 또는 공개 시장 매수에 관한 보고는 없었습니다.

이번 신고는 일상적인 주식 기반 보상 부여를 반영하며 내부자 지분을 소폭 증가시켜 이사의 동기와 주주 이익을 일치시킬 수 있습니다. 다만, 주식이 부여된 것이지 개인 자금으로 구매된 것이 아니므로 거래의 즉각적인 신호 가치는 제한적입니다. 기타 중요한 사건, 재무 지표 또는 소유 구조 변경 사항은 보고되지 않았습니다.

Colony Bankcorp Inc. (CBAN) - Points clés du Formulaire 4 : Le directeur Matthew D. Reed a déclaré l’octroi de 969 actions restreintes le 15/07/2025. Suite à cette attribution, il détient désormais directement 16 736 actions ordinaires, soit une hausse d’environ 6 % par rapport au niveau précédent (~15 767). De plus, Reed détient 448 actions indirectement via un IRA au nom de Kennedy K. Reed. Aucune transaction sur titres dérivés, vente ou achat sur le marché ouvert n’a été divulguée.

Cette déclaration reflète une attribution régulière de rémunération en actions et augmente modestement la détention d’initiés, ce qui peut aligner les intérêts du directeur avec ceux des actionnaires. Toutefois, comme les actions ont été attribuées (et non achetées avec des fonds personnels), la valeur informative immédiate de la transaction est limitée. Aucun autre événement important, indicateur financier ou changement dans la structure de propriété n’a été rapporté.

Colony Bankcorp Inc. (CBAN) Form 4 Highlights: Direktor Matthew D. Reed meldete die Gewährung von 969 eingeschränkten Aktien am 15.07.2025. Nach der Zuteilung besitzt er nun direkt 16.736 Stammaktien, was einem Anstieg von etwa 6 % gegenüber dem vorherigen Bestand (~15.767) entspricht. Zusätzlich hält Reed 448 Aktien indirekt über ein IRA für Kennedy K. Reed. Es wurden keine Derivate, Verkäufe oder Käufe am freien Markt gemeldet.

Die Meldung spiegelt eine routinemäßige aktienbasierte Vergütung wider und erhöht die Insider-Beteiligung moderat, was die Anreize des Direktors mit den Interessen der Aktionäre in Einklang bringen kann. Da die Aktien jedoch gewährt wurden (nicht mit eigenen Mitteln gekauft), ist der unmittelbare Signalwert der Transaktion begrenzt. Es wurden keine weiteren wesentlichen Ereignisse, Finanzkennzahlen oder Änderungen der Eigentümerstruktur gemeldet.

Positive
  • Director ownership rises ~6%, marginally improving management-shareholder alignment
Negative
  • None.

Insights

TL;DR: Routine restricted-stock grant lifts director’s stake 6%; alignment positive but signal limited versus open-market buy.

Restricted stock awards are standard board compensation. Reed’s direct ownership rises to 16,736 shares, keeping directors’ interests aligned with investors. Because no cash outlay was made, market shouldn’t infer the same confidence as an outright purchase. No red flags—no sales, pledges, or derivative positions—so governance risk remains low. Impact: neutral-positive.

TL;DR: Small, non-cash insider acquisition; negligible valuation impact.

The 969-share grant equates to <1% of CBAN’s ~9.0 m shares outstanding, therefore immaterial to float or supply/demand. Because the stock was awarded, not bought, it doesn’t convey incremental bullish sentiment. I view the event as routine and non-impactful for portfolio positioning.

Colony Bankcorp Inc. (CBAN) - Evidenze del Modulo 4: Il direttore Matthew D. Reed ha segnalato la concessione di 969 azioni vincolate il 15/07/2025. Dopo questa assegnazione, detiene ora direttamente 16.736 azioni ordinarie, con un aumento di circa il 6% rispetto al livello precedente (~15.767). Inoltre, Reed possiede 448 azioni indirettamente tramite un IRA intestato a Kennedy K. Reed. Non sono state dichiarate operazioni su titoli derivati, vendite o acquisti sul mercato aperto.

La comunicazione riguarda una concessione ordinaria di azioni come parte della remunerazione basata su equity e incrementa moderatamente la partecipazione interna, potenzialmente allineando gli interessi del direttore con quelli degli azionisti. Tuttavia, poiché le azioni sono state assegnate (e non acquistate con fondi personali), il valore informativo immediato dell’operazione è limitato. Non sono stati riportati altri eventi rilevanti, indicatori finanziari o variazioni nella struttura proprietaria.

Colony Bankcorp Inc. (CBAN) - Destacados del Formulario 4: El director Matthew D. Reed informó la concesión de 969 acciones restringidas el 15/07/2025. Tras esta adjudicación, posee directamente 16,736 acciones comunes, un aumento aproximado del 6% respecto al nivel previo (~15,767). Además, Reed tiene 448 acciones indirectamente a través de una cuenta IRA para Kennedy K. Reed. No se divulgaron operaciones con valores derivados, ventas ni compras en mercado abierto.

La presentación refleja una concesión rutinaria de compensación basada en acciones y aumenta modestamente la propiedad interna, lo que puede alinear los incentivos del director con los intereses de los accionistas. Sin embargo, dado que las acciones fueron otorgadas (y no compradas con fondos personales), el valor informativo inmediato de la transacción es limitado. No se reportaron otros eventos materiales, métricas financieras ni cambios en la estructura de propiedad.

Colony Bankcorp Inc. (CBAN) Form 4 주요 내용: 이사 Matthew D. Reed가 2025년 7월 15일에 969주의 제한 주식 부여를 보고했습니다. 이번 부여 이후 그는 현재 직접 16,736주의 보통주를 보유하고 있으며, 부여 전 약 6%(약 15,767주) 증가한 수치입니다. 또한 Reed는 Kennedy K. Reed 명의의 IRA를 통해 간접적으로 448주를 보유하고 있습니다. 파생 증권, 매도 또는 공개 시장 매수에 관한 보고는 없었습니다.

이번 신고는 일상적인 주식 기반 보상 부여를 반영하며 내부자 지분을 소폭 증가시켜 이사의 동기와 주주 이익을 일치시킬 수 있습니다. 다만, 주식이 부여된 것이지 개인 자금으로 구매된 것이 아니므로 거래의 즉각적인 신호 가치는 제한적입니다. 기타 중요한 사건, 재무 지표 또는 소유 구조 변경 사항은 보고되지 않았습니다.

Colony Bankcorp Inc. (CBAN) - Points clés du Formulaire 4 : Le directeur Matthew D. Reed a déclaré l’octroi de 969 actions restreintes le 15/07/2025. Suite à cette attribution, il détient désormais directement 16 736 actions ordinaires, soit une hausse d’environ 6 % par rapport au niveau précédent (~15 767). De plus, Reed détient 448 actions indirectement via un IRA au nom de Kennedy K. Reed. Aucune transaction sur titres dérivés, vente ou achat sur le marché ouvert n’a été divulguée.

Cette déclaration reflète une attribution régulière de rémunération en actions et augmente modestement la détention d’initiés, ce qui peut aligner les intérêts du directeur avec ceux des actionnaires. Toutefois, comme les actions ont été attribuées (et non achetées avec des fonds personnels), la valeur informative immédiate de la transaction est limitée. Aucun autre événement important, indicateur financier ou changement dans la structure de propriété n’a été rapporté.

Colony Bankcorp Inc. (CBAN) Form 4 Highlights: Direktor Matthew D. Reed meldete die Gewährung von 969 eingeschränkten Aktien am 15.07.2025. Nach der Zuteilung besitzt er nun direkt 16.736 Stammaktien, was einem Anstieg von etwa 6 % gegenüber dem vorherigen Bestand (~15.767) entspricht. Zusätzlich hält Reed 448 Aktien indirekt über ein IRA für Kennedy K. Reed. Es wurden keine Derivate, Verkäufe oder Käufe am freien Markt gemeldet.

Die Meldung spiegelt eine routinemäßige aktienbasierte Vergütung wider und erhöht die Insider-Beteiligung moderat, was die Anreize des Direktors mit den Interessen der Aktionäre in Einklang bringen kann. Da die Aktien jedoch gewährt wurden (nicht mit eigenen Mitteln gekauft), ist der unmittelbare Signalwert der Transaktion begrenzt. Es wurden keine weiteren wesentlichen Ereignisse, Finanzkennzahlen oder Änderungen der Eigentümerstruktur gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Silverman Peter B.

(Last) (First) (Middle)
C/O MERUS N.V.
UPPSALALAAN 17

(Street)
UTRECHT P7 3584 CT

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Merus N.V. [ MRUS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
COO & GC
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 07/17/2025 M(1) 25,000 A $24.43(2) 25,000 D
Common Shares 07/17/2025 S(1) 25,000 D $60(3) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (right to buy) $24.43 07/17/2025 M(1) 25,000 (4) 02/16/2031 Common Shares 25,000 $0 50,000(5) D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025.
2. Represents the exercise price of the options originally granted on February 16, 2021.
3. Amount represents the weighted average price of shares sold, which ranged from $60.00 to $60.07. Details of individual transactions are available upon request.
4. The options are fully vested and exercisable.
5. Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 16, 2021.
/s/ Peter Silverman as attorney-in-fact 07/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CBAN shares did Director Matthew D. Reed acquire?

He received 969 restricted shares on 07/15/2025.

What is Reed’s total direct ownership after the transaction?

He now directly holds 16,736 CBAN common shares.

Were any CBAN shares sold in this Form 4?

No. The filing only reports an acquisition; there were no dispositions.

Does the filing include derivative securities or options?

No derivative securities were reported; the table for derivatives is blank.

Is the acquisition an open-market purchase?

No, it is a restricted stock award grant, part of board compensation.
Merus

NASDAQ:MRUS

MRUS Rankings

MRUS Latest News

MRUS Latest SEC Filings

MRUS Stock Data

4.10B
71.67M
2.04%
106.48%
10.72%
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
3584 CM UTRECHT